At the IGTP TODAY

News

Two projects at the IGTP and IDIAP Jordi Gol research centres focus on the immune response of health professionals to infection with SARS-CoV-2

The IGTP has received funding in the extraordinary call published by the Department of Research and Innovation of the Department of Health (DGRIS) with the collaboration of AQuAS and Biocat and aimed at all the Iriscat centres for research into coronavirus. The two projects, focussed on the immune response of health professionals on the frontline with the virus, have joined the forces of the IGTP, IrsiCaixa and research and healthcare in the context of primary and hospital healthcare. A third project, led by Dr Julià Blanco, researcher at IrsiCaixa and the IGTP has also received funding.

Respira, the new ventilator device developed gets the go ahead from the AEMPS for clinical trials

The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved a clinical trial with the ventilation device RESPIRA developed by GAPInnova with the support of professionals from the Hospital Clínic Barcelona, the Germans Trias I Pujol Research Institute and the University of Barcelona. This is the second device developed with the support of these organizations to be approved by the AEMPS for testing on patients at the Hospital Clinic Barcelona and at Can Ruti. The prototype of the RESPIRA device mechanizes manual ressusitations with AMBU devices providing automatic respiration assistance and monitoring.

- Research

IGTP researchers study the impact of the COVID-19 epidemic on people through a citizen survey

Researchers of the Experimental Tuberculosis Unit at the IGTP have launched a questionnaire to ask the public who they are being affected by the pandemic. The project, led by Dr Cristina Vilaplana, will collect replies from the public using a standard questionnaire to evaluate the impact of the pandemic on people, including healthcare workers including effects on health, emotional wellbeing and family finances.

- Innovation, Institutional

New ventilator device developed by the Hospital Clínic, Germans Trias i Pujol and Barcelona University with Protofy.xyz gets the go ahead from the AEMPS for clinical trials

The Spanish Agency of Medicines and Medical Devices (AEMPS) approves a clinical trial with the emergency ventilator device developed by the Barcelona company Protofy.xyz with the financial and scientific support of professionals from the Hospital Clínic Barcelona, the Germans Trias i Pujol hospital and the University of Barcelona. It is a device to automate manual ventilation processes and provide respiratory support for patients in emergency situations when conventional ventilators are unavailable. The support received from civil society, companies and administrations has been key in developing the design and industrial scaling of this model, which will contribute to providing the health system with the necessary ventilators.

- Innovation, Institutional

Can Ruti Campus, Hospital Clínic Barcelona and Barcelona University collaborate in a Ministry of Health project to develop emergency ventilators

The Germans Trias i Pujol and Clínic Barcelona Hospitals and the University of Barcelona are providing scientific support to develop a device that allows patients to be ventilated in the absence of conventional ventilators. Three Catalan companies (Protofy.xyz, GASN2 and Innova) are creating and adapting emergency models of ventilators to deal with the crisis caused by COVID-19. The three proposals are now in the simulation and experimental phases. When they have completed all the validations and have obtained the authorization of the Spanish Agency of Medicines and Medical Devices (AEMPS) production will start on industrial scale. Support from civil society will be key in developing the three models and financing production to contribute to providing the Catalan health system with the ventilators needed.

- Research

A team including researchers at the IGTP confirm new ways to test and treat TB by harnessing the body’s own defences

In new study in a cohort of patients from Southern Europe, researchers including the innovation in Respiratory Infections and Tuberculosis Diagnosis Group at the IGTP have confirmed the importance of exploring immune pathways other than the ones modulated by interferon-gamma, which is the one that has been most studied in work on TB until now. The study published in Frontiers of Immunology has also hinted at ways to differentiate between latent and active TB, a major goal in the battle against the disease.

The IGTP is working to respond to COVID-19

The Germans Trias I Pujol Research Institute (IGTP) is working alongside the hospital and at the service of the Ministry of Health of the Government of Catalonia to make all the necessary disposable material and resources available for the diagnosis and treatment of COVID-19. The research groups at the centre are also working against the clock to prepare projects for the extraordinary competitive funding calls that have been issued to fund research into SARS-CoV-2 and the disease COVID-19.

- Projects, Research

Researchers at the UPC and the IGTP use mathematical models to evaluate the evolution of the COVID-19 epidemic and the effectiveness of the control measures

A team of researchers from the Computational Biology and Complex Systems research group (BIOCOM-SC) of the UPC and the Centre for Comparative Medicine and Bioimage (CMCiB) of the Germans Trias i Pujol Research Institute (IGTP) with the support of "la Caixa" Foundation, have developed a mathematical model to follow up the epidemic of COVID-19. The report that they have produced for the Strategy Office of the European Union is updated every day and includes predictions for Catalonia, Spain and the European Union. The model also serves to analyze the efficiency of the measures being established by different countries